Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 6/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140434 | 0.90 | L3MBTL1 (0.46) | L3MBTL1TP53MAPTELANECYP1A2 | |
| SCHEMBL20140783 | 0.88 | L3MBTL1 (0.63) | L3MBTL1ELANEKAT2BAPPSNCA | |
| SCHEMBL20140381 | 0.87 | ELANE (0.56) | L3MBTL1ELANEKAT2BAPPSNCA | |
| SCHEMBL2883465 | 0.86 | MAPT (0.51) | L3MBTL1MAPTELANECYP1A2CYP2C19 | |
| SCHEMBL20140776 | 0.84 | ELANE (0.42) | L3MBTL1MAPTELANE | |
| SCHEMBL9925005 | 0.84 | L3MBTL1 (0.49) | L3MBTL1MAPTELANEKDM4EPTGDR2 | |
| SCHEMBL2881342 | 0.83 | ELANE (0.41) | L3MBTL1TP53MAPTELANE | |
| SCHEMBL2877930 | 0.83 | ELANE (0.41) | L3MBTL1MAPTELANEKDM4E | |
| SCHEMBL2882941 | 0.82 | ELANE (0.44) | L3MBTL1MAPTELANEKDM4E | |
| SCHEMBL20140277 | 0.82 | ELANE (0.46) | L3MBTL1ELANEAPPSNCARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885TP53 4425/4885MAPT 4780/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885TP53 4394/4885MAPT 4786/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885TP53 4394/4885MAPT 4786/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | L3MBTL1 4698/4885TP53 4425/4885MAPT 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.